Merck Group account plan
Healthcare lifescience electronics solutions
At a glance
Merck KGaA is a family-controlled German science and technology group in Life Science, Healthcare and Electronics, with €21,102 million of 2025 sales.
Merck KGaA, Darmstadt, Germany, is a science and technology company founded in 1668 that works in three sectors: Life Science, Healthcare and Electronics. In the US and Canada it operates as MilliporeSigma, EMD Serono and EMD Electronics. In FY2025 it reported net sales of €21,102 million (organic +3.1%), EBITDA pre of €6,109 million (28.9% margin) and profit after tax of €2,615 million; Asia-Pacific (€6,936 million) and Europe (€6,417 million) were its largest regions. It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026. The founding family holds 70.274% via E. Merck KG, and 29.726% of the share capital is listed in Frankfurt; Kai Beckmann has been Group CEO since 1 May 2026.
Business units
Life Science
€8,980 million FY2025 sales, 42% of group sales, 40% of EBITDA preReagents, consumables, instruments, filtration, chromatography and single-use systems, and contract testing and manufacturing for labs, biotech and pharma (MilliporeSigma in North America). Since 1 January 2026 it reports as Process Solutions, Discovery Solutions and Advanced Solutions; H1 2026 sales were €4,677 million (organic +8.1%), with Process Solutions up 15.5% organically. Led by Jean-Charles Wirth.
Healthcare
€8,607 million FY2025 sales, 41% of group sales, 47% of EBITDA preSpecialty medicines (EMD Serono in the US and Canada) now organised in four franchises: Rare Diseases, Cardiometabolic, Fertility & Endocrinology and Specialty Care. H1 2026 sales were €4,203 million (organic -3.4%) as US generics hit Mavenclad, offset by the SpringWorks rare-disease portfolio. Led by Dan Pinhas Bar Zohar.
Electronics
€3,515 million FY2025 sales, 17% of group sales, 13% of EBITDA preMaterials, delivery systems and metrology and inspection for semiconductor and display makers, a pure-play business since Surface Solutions was sold in July 2025; Asia-Pacific generated 72% of sector sales. Semiconductor Solutions grew 12.2% organically in H1 2026 on AI-driven advanced nodes. Benjamin Hein succeeded Kai Beckmann as CEO Electronics.
Strategic priorities
- Three growth drivers
- Process Solutions, Rare Diseases and Semiconductor Solutions are positioned to generate up to 80% of growth in the medium term, with mid-single-digit organic sales growth targeted.
- New strategic direction (May 2026)
- Four streams: focus on high-growth value drivers, shift selected portfolios to integrated workflow solutions, platform capabilities across businesses such as AI deployment, and sourcing innovation through M&A and in-licensing.
- Integrated workflow solutions
- Merck is moving selected portfolios from standalone products to end-to-end offerings, as in bioprocessing (consumables, bioreactors, process analytics software) and in materials plus metrology for advanced chips.
- Healthcare pipeline and margin
- Healthcare stays above a 30% EBITDA pre margin while R&D moves towards 25% of sales, with pipeline building focused on early and mid-stage external innovation.
- Sustainability
- Climate neutrality by 2040; Scope 1 and 2 emissions are down 60% versus 2020, with renewable purchased electricity at 64% toward 80% by 2030.
Latest results
In H1 2026 net sales were €10,568 million (+0.3%; organic +3.5%) and EBITDA pre €3,129 million (+4.4%; organic +7.2%), a 29.6% margin; free cash flow rose to €565 million from €194 million. Q2 2026 sales grew 4.1% organically to €5,434 million, while EBIT fell 15.5% to €753 million on €189 million of restructuring expenses. Life Science and Electronics grew organically while Healthcare declined on US Mavenclad generics. Guidance was raised for the second time to net sales of €21.0-21.8 billion, EBITDA pre of €5.9-6.3 billion and EPS pre of €7.90-8.60. Net financial debt was €9,207 million at 30 June 2026.
Investments and deals
- Bio-Techne acquisition
- Agreed on 25 June 2026 at US$73 per share, a company value of around US$11.3 billion (€9.9 billion); close expected end-2026/early 2027, with run-rate cost synergies of approximately €140 million by year three.
- SpringWorks Therapeutics
- Acquired on 1 July 2025 for an enterprise value of approximately €3 billion, creating the Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly).
- JSR chromatography business
- Acquisition of JSR Corporation's chromatography business (Amsphere Protein A resins) completed in March 2026.
- Manufacturing sites
- Over €7 billion invested in over 30 new or expanded sites since 2021, including the €500 million Kaohsiung megasite in Taiwan and a €150 million filter plant at Blarney, Cork.
- Surface Solutions divestment
- Pigments business sold to Global New Material International Holdings for €669 million, closed 31 July 2025.
Challenges and risks
- Mavenclad generics in the US
- Two US dosing-regimen patents were held invalid, opening the market to generics; 2026 guidance assumes no US Mavenclad sales from August 2026.
- Currency headwinds
- Currency effects cut FY2025 sales by 3.7%, pushing sales below the original guidance.
- Geopolitics and supply chain
- Risks include Russia-Ukraine, the Taiwan Strait, US-China export controls, and the Gulf conflict and Strait of Hormuz for supply chains and raw materials.
- Pricing and competition
- Drug pricing pressure, overcapacity and price pressure in bioprocessing, semiconductor cyclicality and Chinese competition are listed among the most significant risks.
- Weak lab and consumer electronics demand
- US policy changes affecting academic and government labs and a weak China held Science & Lab Solutions flat, and weak consumer electronics hit Optronics.
What leadership says
“only a clear plan and disciplined execution will move us closer to the sustainable, profitable growth we are building for our company.”
“In short, we will optimize for speed and scalability where it matters.”
“Most importantly, we transform in times of growth.”
Where a supplier can help
- Bio-Techne integration
- Integration is the stated priority after the Bio-Techne deal, with about €140 million of cost synergies targeted, a fit for integration, systems and process consultancies.
- AI platform capabilities
- AI deployment is one of the shared platform capabilities in the new strategic direction, opening doors for data, AI and digital workflow suppliers.
- Integrated workflow offerings
- The shift from standalone products to end-to-end offerings in bioprocessing and chip materials creates room for software, analytics and equipment partners.
- New plant start-ups
- Startup of new sites such as Blarney in Ireland and Kaohsiung in Taiwan, and the move from building to loading capacity, needs automation, maintenance and operations support.
- Supply-chain resilience
- Geopolitical and Strait of Hormuz supply-chain risks point to demand for sourcing, logistics and raw-material risk services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Merck Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Merck Annual Report 2025
- Merck KGaA (Darmstadt) is a science and technology group with three business sectors, Life Science, Healthcare and Electronics; the founding family, in its 13th generation, holds 70.274% via E. Merck KG, and 29.726% of the share capital trades on the Frankfurt Stock Exchange. In the US and Canada it operates as MilliporeSigma, EMD Serono and EMD Electronics. 62,461 employees at 31 December 2025.
- FY2025: net sales €21,102 million (-0.3%; organic +3.1%, currency -3.7%, portfolio +0.4%), EBITDA pre €6,109 million (+0.6%; organic +5.6%) at a 28.9% margin, profit after tax €2,615 million, EPS pre €8.34, operating cash flow €3,932 million (-14.3%). Dividend proposed unchanged at €2.20.
- Sector mix: Life Science 42% of sales / 40% of EBITDA pre, Healthcare 41% / 47%, Electronics 17% / 13%. By region: Asia-Pacific €6,936 million, Europe €6,417 million, North America €5,517 million, Latin America €1,447 million, Middle East and Africa €785 million.
- Life Science (€8,980 million) returned to growth: Process Solutions grew 10.7% organically on new customer projects and a normalizing market; a customer-centric structure (Process Solutions, Discovery Solutions, Advanced Solutions) took effect on 1 January 2026. Acquisition of JSR Corporation's chromatography business signed.
- Healthcare (€8,607 million, EBITDA pre margin 35.8%): SpringWorks Therapeutics acquired on 1 July 2025 (enterprise value of approximately €3 billion), creating a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly); Mavenclad reached €1,194 million but two US dosing-regimen patents were held invalid, opening the US to generics.
- Electronics (€3,515 million) is now a pure-play semiconductor and optronics business after selling Surface Solutions (closed 31 July 2025, €669 million); Semiconductor Materials grew 8.2% organically on AI demand, while Delivery Systems & Services fell on delayed customer projects; €500 million Kaohsiung (Taiwan) megasite inaugurated.
- Strategy: three growth drivers (Process Solutions, Rare Diseases, Semiconductor Solutions) expected to generate up to 80% of medium-term growth; mid-single-digit organic sales growth targeted over the medium term; capex-to-sales to normalize after €7 billion invested in over 30 sites since 2021.
- Net financial debt rose to €8,619 million (SpringWorks; US$4 billion bond in August 2025); ratings A (S&P) and A3 (Moody's). Dividend policy: 20% to 25% of EPS pre.
- 2026 outlook (March): net sales €20.0-21.1 billion (organic -1% to +2%), EBITDA pre €5.5-6.0 billion, free cash flow €1.5-2.0 billion (new KPI); Healthcare to decline organically on US Mavenclad generics. Kai Beckmann succeeds Belén Garijo as CEO on 1 May 2026.
- Half-Yearly Financial Report 2026 (Q2 2026)
- H1 2026: net sales €10,568 million (+0.3%; organic +3.5%, currency -3.3%), EBITDA pre €3,129 million (+4.4%; organic +7.2%), margin 29.6%; EPS pre €4.27; free cash flow €565 million (H1 2025: €194 million).
- Q2 2026: sales €5,434 million (+3.4%, organic +4.1%), EBITDA pre €1,599 million (+9.4%, organic +9.3%), margin 29.4%; EBIT fell 15.5% to €753 million on €189 million of restructuring expenses.
- Life Science H1 sales €4,677 million (organic +8.1%): Process Solutions +15.5% organic (€2,082 million) on downstream and single-use demand, Discovery Solutions +1.8%, Advanced Solutions +4.2%; EBITDA pre margin 28.8%.
- Healthcare H1 sales €4,203 million (organic -3.4%, SpringWorks portfolio effect +4.9%): Specialty Care -6.3% (Mavenclad generics in the US, Bavencio), Rare Diseases €209 million; EBITDA pre down 7.2% to €1,465 million (margin 34.9%) with R&D up 23.1%.
- Electronics H1 sales €1,688 million (organic +7.9%): Semiconductor Solutions +12.2% organic on AI-driven advanced nodes, Optronics -2.3%; EBITDA pre €526 million (+39.2%), margin 31.2%, helped by €43 million from selling OLED patents.
- Bio-Techne: agreement (25 June 2026) to buy Bio-Techne for US$73 per share, a company value of around US$11.3 billion (€9.9 billion); close expected end-2026/early 2027. JSR chromatography acquisition closed; Saturnus Bio controlled from June 2026.
- Guidance raised: net sales €21.0-21.8 billion (organic +1% to +3%), EBITDA pre €5.9-6.3 billion, free cash flow €1.8-2.3 billion, EPS pre €7.90-8.60.
- Kai Beckmann became Chairman of the Executive Board and Group CEO on 1 May 2026; Benjamin Hein succeeded him as CEO Electronics. Net financial debt €9,207 million; 62,136 employees.
- Q2 2026 investor and analyst conference call (transcript)
- Kai Beckmann, Group CEO since May 2026, called Q2 "a pretty robust quarter": organic sales +4.1%, organic EBITDA pre +9.3%, margin up 1.6 points to 29.4%; full-year guidance raised for the second time.
- Bio-Techne (signed 25 June) is his first big proof point: expected to add close to 5% to group sales growth and about 10% to Life Science, immediately accretive to the EBITDA pre margin, EPS pre accretive in year three, run-rate cost synergies of about €140 million.
- Process Solutions grew 15% organically, helped by temporary Asian buying, exceptional China equipment orders and one-off integrated-workflow orders; full year expected at the upper end of the 8% to 12% range, with any destocking more likely in 2027.
- Electronics: Semiconductor Solutions +17% organic on AI-driven advanced logic and memory; leading-edge customers capacity-constrained into 2027; memory shortage seen lasting at least to H2 2027; Optronics hit by weak consumer electronics.
- Healthcare: Mavenclad US eroding more slowly than analogs, Europe up 32% in Q2; Pergoveris US filing accepted but approval uncertain; the anti-CEACAM5 ADC will be developed alone rather than partnered.
- 2027: Beckmann says organic growth should be in line with the 2025 Capital Markets Day projections, despite tough Mavenclad and Process Solutions comparisons.
- Priorities after Bio-Techne: integration, replenishing the early-stage healthcare pipeline, strengthening Life Science and Electronics; CFO flags fast deleveraging after closing.
- Q1 2026 investor and analyst conference call, with strategic direction update (transcript)
- First call as Group CEO (13 May 2026): Kai Beckmann called Q1 "a solid start to 2026 despite global challenges" (organic sales +2.9%, organic EBITDA pre +5.3%) and raised 2026 guidance to €20.4-21.4 billion sales and €5.7-6.1 billion EBITDA pre.
- Unveiled a new strategic direction built on four streams: focus on high-growth value drivers, shift selected portfolios to integrated workflow solutions, platform capabilities across businesses, and sourcing innovation through M&A and in-licensing.
- Framing: AI compresses discovery, so advantage shifts to companies that can "rapidly validate, manufacture, scale, and commercialize innovations"; Merck positions itself as both an enabler and a user of AI.
- Mid-term guidance from the 2025 Capital Markets Day confirmed; strategy impact expected progressively, with a standalone investor event planned for next year.
- M&A scope broadened but disciplined: IRR above WACC, EPS pre accretion after synergies, strong investment-grade rating; expansion into equipment and tools only where it drives materials and consumables.
- Healthcare: kept above 30% EBITDA pre margin while R&D moves toward 25% of sales; pipeline building focused on early and mid-stage; four new franchises (Rare Diseases, Cardiometabolic, Fertility & Endocrinology, Specialty Care).
- Process Solutions +16% in Q1 (above €1 billion of quarterly sales for the first time since Q1 2023); semiconductor materials grew double digit; Middle East and Africa only 3% of group sales.
- Q4 and full-year 2025 investor and analyst conference call (transcript)
- Full-year 2025 call (5 March 2026), Belén Garijo's last as CEO: 2025 delivered solid organic sales and EBITDA pre growth in a challenging macro and geopolitical environment, meeting the latest guidance for the group and all sectors.
- Q4 2025: organic sales +2.6%, organic EBITDA pre +3.1%; leverage improved to 1.4 times net debt to EBITDA pre; stable €2.20 dividend proposed, a 15th year of stable or rising dividends.
- Garijo: Life Science back to growth (Process Solutions around 10% organic in 2025); Rare Diseases a new Healthcare pillar; Electronics now a pure-play business "right at the center of the rise in artificial intelligence".
- Healthcare committed to EBITDA pre margins north of 30% and R&D around 20% of sales; three growth engines: Rare Diseases, CM&E and Fertility.
- Kai Beckmann (incoming CEO) gave 2026 guidance: sales €20-21.1 billion, EBITDA pre €5.5-6 billion, EPS pre €7.10-8, assuming no US Mavenclad sales from March and excluding a US Pergoveris launch.
- Sustainability: Scope 1 and 2 emissions down 60% versus 2020; more than 5,000 greener Life Science products with over €300 million of sales.
- Garijo's legacy claim: sales up 20% since 2020, earnings faster and net debt down 20%, via a "string of pearls" M&A approach (Mirus Bio, Unity-SC, SpringWorks).
- Belén Garijo's prescription for Germany's Merck (Semafor, The Signal Interview)
- Semafor's "Signal Interview" (14 November 2025) with Belén Garijo, then CEO, as she prepared to hand over to Kai Beckmann in May 2026.
- Her diagnosis approach comes from medicine: "I act on the root cause rather than on the symptoms."
- Family ownership (13th generation, board of partners approving large capital allocation) supports long-term decisions and a shift from scale acquisitions to a "string of pearls" approach; it let her resist pressure to do more life science deals a few years ago.
- "Most importantly, we transform in times of growth": cost and efficiency work started during the pandemic boom.
- Defends the three-sector model as "a risk-reward model that fits… family ownership"; acknowledges a "conglomerate discount" and answers it with synergies in manufacturing, innovation and AI ("bioconvergence").
- Built a "One Merck" culture: cross-sector talent moves, group-wide incentive scorecard, joint work among the three R&D heads; almost 40% of senior leaders are women.
- Will not rename the company: "we are Merck. The real Merck." Merck's US arm agreed with the White House to cut prices of some IVF drugs.
Questions about Merck Group
What does Merck KGaA do?
Merck KGaA, Darmstadt, Germany, is a science and technology company in Life Science, Healthcare and Electronics, operating in the US and Canada as MilliporeSigma, EMD Serono and EMD Electronics.
What was Merck KGaA's revenue in 2025?
Net sales were €21,102 million in FY2025, with EBITDA pre of €6,109 million and profit after tax of €2,615 million.
How many employees does Merck KGaA have?
It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026.
Who leads Merck KGaA?
Kai Beckmann became Chairman of the Executive Board and Group CEO on 1 May 2026, succeeding Belén Garijo; Helene von Roeder is CFO.
What is Merck KGaA's strategy?
It focuses on three growth drivers (Process Solutions, Rare Diseases, Semiconductor Solutions), integrated workflow solutions and M&A such as the Bio-Techne deal, targeting mid-single-digit organic growth.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)